TITLE

Saving Your Liver

AUTHOR(S)
Dolan, Kerry A.
PUB. DATE
November 2006
SOURCE
Forbes Asia;11/27/2006, Vol. 2 Issue 20, p62
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the need for pharmaceutical firms to develop drugs that will cure hepatitis C. There are many side effects of interferon, a standard drug used to treat the liver disease hepatitis C. The cure can feel worse than the disease. Human Genome Sciences partnered with Swiss pharmaceutical giant Novartis to jointly commercialize Albuferon in the U.S. Novartis will sell the drug outside the U.S.
ACCESSION #
23288865

 

Related Articles

  • Reading the Tea Leaves for Interferon's Future in HCV. Morrison, Trista // BioWorld Insight;10/11/2010, Vol. 18 Issue 41, p1 

    The article focuses on the availability of interferons in the market as several of them were halted prior to various issues. It cites Zalbin, whose manufacturers Human Genome Sciences Inc. (HGSI) and Novartis AG dropped its future development, adding that it carried lower sustained virologic...

  • Weighing the Impact: HGSI's Double Dose of Bad News. Morrison, Trista // BioWorld Insight;4/26/2010, Vol. 18 Issue 17, p1 

    The article provides an analysis concerning the negative news received by biopharmaceutical firm Human Genome Sciences Inc. (HGSI) when its partner Novartis AG withdrew its European marketing application for hepatitis C drug Zalbin and lupus drug Benlysta. It mentions that the case of Zalbin is...

  • Novartis: continuing its infectious diseases drive.  // PharmaWatch: Monthly Review;Jul2006, Vol. 5 Issue 7, p39 

    The reports on the global agreement of Swiss pharmaceutical firm Novartis with U.S.-based Human Genome Sciences for hepatitis C drug candidate Albuferon. The company made an offer for UK-based anti-infectives developer NeuTec Pharma. Novartis has in-licensed global marketing rights for the...

  • Novartis: building its antiviral arsenal.  // PharmaWatch: Monthly Review;Jul2006, Vol. 5 Issue 7, p39 

    The article reports on the licensing deal of Swiss pharmaceutical firm Novartis with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate, with exclusive marketing and promotion rights outside in the U.S. The investigational drug is in phase...

  • Interferon Filing Done as HGS Revs Benlysta.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p2 

    The article reports that Human Genome Sciences Inc. (HGS), has filed the biologics license application (BLA) for hepatitis C drug Zalbin, instead of highly demanding BLA for lupus drug Benlysta. Various examples of the studies related to the quantity of Zalbin to be given to the patients, is...

  • HGS, Novartis Bail on Zalbin After Thumbs Down from FDA. Shaffer, Catherine // BioWorld Today;10/6/2010, Vol. 21 Issue 193, p1 

    The article reports on the decision of Rockville, Maryland-based Human Genome Sciences Inc. (HGS) and Basel, Switzerland-based Novartis to discontinue the development of Zalbin albinterferon alfa-2b for the treatment of hepatitis C. The drug was turned down by the U.S. Food and Drug...

  • INDUSTRY UPDATE. Smith, Davis N. // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p178 

    Presents information on the pharmaceutical industry as of April 2001. Completion of the construction of the Human Genome Sciences' facility to manufacture its antibody therapies; Decision of Pharmacia to merge its pharmaceutical units Global Country Operations and Global Business Management;...

  • Manic Monday: Idenix HCV Win Could Let HGS Salvage Its Deal. Osborne, Randy // BioWorld Insight;7/20/2009, Vol. 17 Issue 29, p1 

    The article focuses on the future of the deal of Human Genome Sciences Inc. (HGS) with Novartis AG for the hepatitis C virus (HCV) drug, Albuferon. It states that HGS was expected to report results from a Phase III trial with lupus drug Benlysta, and Idenix Pharmaceuticals Inc., a Novartis HCV...

  • Less-Often Interferon Filing Done as HGS Revs Benlysta. Morrison, Trista // BioWorld Today;11/30/2009, Vol. 20 Issue 229, p1 

    The article reports that Human Genome Sciences Inc. (HGS) has filed a biologics license application (BLA) for Zalbin (albinterferon alfa-2b), a drug for hepatitis C. The role of the albumin-infusion technology of HGS in Zalbin formerly known as Albuferon is noted. It compares the findings of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics